First integrase inhibitor Isentress gets regulatory green light
Raltegravir (Isentress, Merck) receives FDA approval for HIV treatment.
Priority review of Hycamtin leads to FDA nod for SCLC
Topotecan granted FDA approval for relapsed small cell lung cancer.
Rite Aid and Lindora to open five clinics in southern California
Rite Aid and Lindora to expand California in-store clinics.
Walgreen Co. receives NABP accreditation for DMEPOS
NABP awards DMEPOS accreditation to Walgreen Co.
Homeopathic firms hope to capitalize on OTC withdrawal
Makers of homeopathic products push their cough and cold remedies in the wake of the withdrawal OTC cough and cold products for infants.
New report damning to Part D private insurers
A new report requested by Rep. Henry Waxman finds that private insurers are not operating their Medicare Part D programs efficiently.
NCPA's Roberts calls for optimism amid difficulty
NCPA CEO Bruce Roberts urges members to get more involved in medication therapy management, e-prescribing, and lobbying legislators at annual convention.
Staffing and service rose at independent pharmacies in 2006
Although the number of independent pharmacies has decreased from 2006, salary levels for pharmacists and technicians have increased.
Former airline maintenance center becomes specialty pharmacy
WellPoint opens specialty pharmacy in airport
False claims lead marshals to seize $71,000 worth of supplements
Dietary supplements confiscated by FDA
NCPA political powerhouse John Rector to retire next year
John Rector plans to step down from his position as general counsel for NCPA in 2008
Beware of new warnings for contrast agents
FDA issues new warnings about Definity and Optison contrast agents
Medicaid spending remains flat
States look to expand Medicaid benefits and eligibility as the program enrollment and spending remain low.
Consumers Union finds fault with Part D ratings
Consumers Union, publisher of Consumer Reports, criticizes the Centers for Medicare & Medicaid Service's system for rating Medicare Part D prescription drug plans as meaningless.
Outcomes upgrades MTM system
Outcomes Pharmaceutical Health Care has released a new version of its medication therapy management (MTM) systems.
Manufacturer cuts off compounding pharmacies' access to its drug
The eye care community is disconcerted by Genentech's decision to restrict access to its cancer drug Avastin.
CMS slow to investigate PDP fraud
OIG report finds the Centers for Medicare & Medicaid Services was slow to respond to fraud allegations against prescription drug plans and lacked an antifraud strategy.
MMWR reports on colchicine deaths due to compounding error
Three deaths determined to be result of colchicine toxicity
Maryland R.Ph.s seek fix for flawed Medicaid reimbursement rule
Maryland pharmacists urge House Majority Leader Hoyer to put patients first
Kids use of GI meds on the rise
Children are using more medications to treat gastrointestinal problems
NAPLEX reinstated
The National Association of Boards of Pharmacy has reinstated the North American Pharmacist Licensure Exam at all the Prometric testing centers.
CMS releases details on 2008 Part D plans
The Centers for Medicare & Medicaid Services has released an improved plan finder with details on 2008 Medicare Part D prescription drug plans.
Two regional chains tie the knot
Two Hispanic pharmacy chains combine under Navarro name
Several companies voluntarily withdraw infant cough and cold OTCs
Several manufacturers withdraw over-the-counter cough and cold products
Warnings strengthened for Zyprexa and Symbyax
New metabolic warnings added to olanzapine product labels
First generic Trileptal products get FDA nod
First oxcarbazepine receives approval for seizure disorders
NACDS' Robert J. Bolger has passed away
Robert J. Bolger has died
Legislators introduce bill to reverse CMS decision on ESA coverage
Battle over ESA coverage continues
Medi-Promotions expands Medi-Scripts prescription pad model
Medi-Promotions to launch Medi-Scripts Plus prescription pad
Full approval granted for Aptivus
FDA grants full approval of tipranavir.
